Adherence and persistence of HIV pre‐exposure prophylaxis use in the United States

• Published in: Pharmacoepidemiology and drug safety 2024-01, Vol.33 (1), p.e5729-n/a
• Main Authors: McCormick, Carter D., Sullivan, Patrick S., Qato, Dima M., Crawford, Stephanie Y., Schumock, Glen T., Lee, Todd A.
• Format: Article
• Language: English
• Subjects: adherence; Age groups; Anti-HIV Agents - therapeutic use; claims analysis; Female; HIV; HIV Infections - drug therapy; HIV Infections - epidemiology; HIV Infections - prevention & control; HIV/AIDS; Human immunodeficiency virus; Humans; Male; Medication Adherence; Middle Aged; persistence; Pre-Exposure Prophylaxis; Prophylaxis; Retrospective Studies; United States - epidemiology
• ISSN: 1053-8569; 1099-1557; 1099-1557
• DOI: 10.1002/pds.5729

Purpose To describe medication adherence and persistence of HIV PrEP overall and compare between sex and age groups of commercially insured individuals in the United States. Methods We conducted a national retrospective cohort study of the Merative MarketScan Claims Database from 2011 to 2019 to describe adherence and persistence of PrEP overall and compared between sex and age groups. High adherence was defined as ≥80% of proportion of days covered and persistence was measured in days from initiation to the first day of a 60‐day treatment gap. Results A total of 29 689 new PrEP users identified. Overall adherence was high (81.9%; 95% confidence interval [CI]: 81.5%–82.3%). Females were more adherent than males (adjusted odds ratio [aOR] 1.87; 95% CI: 1.50–2.34), while those ≥45‐years were less adherent than individuals